読み込み中
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
前日終値
$12.545
+$0.525 · +4.37%
日中の時刻はETです。市場データは遅延する場合があります。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日中レンジ
現在 $12.545
52週レンジ
現在 $12.545
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
63
強気
リスク
49
やや高いリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
日中レンジ
現在 $12.545
52週レンジ
現在 $12.545
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$14.75
上昇余地（17.58%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Biotechnology ETFIBB2322.89万0.22%108.2億 USD0.44%$206.49+3.00%
iShares Genomics Immunology and Healthcare ETFIDNA822.42万2.58%3.2億 USD0.47%$42.17+4.33%
State Street SPDR Portfolio Developed World ex-US ETFSPDW691.13万0.02%404.62億 USD0.03%$49.98+0.64%
Fidelity Nasdaq Composite Index ETFONEQ104.5万0.01%109.4億 USD0.21%$107.81+0.63%
Avantis U.S. Equity ETFAVUS77.9万0.01%148.63億 USD0.15%$130.52+0.35%
Virtus Biotech Clinical Trials ETFBBC72.79万1.78%4099.65万 USD0.65%$44.1456+2.08%
Avantis U.S. Small Cap Equity ETFAVSC47.67万0.02%30.82億 USD0.25%$69.98+0.03%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN37.5万0.11%3.47億 USD0.47%$45.715+0.83%iShares Biotechnology ETFIBBiShares Genomics Immunology and Healthcare ETFIDNAState Street SPDR Portfolio Developed World ex-US ETFSPDWFidelity Nasdaq Composite Index ETFONEQAvantis U.S. Equity ETFAVUSVirtus Biotech Clinical Trials ETFBBCAvantis U.S. Small Cap Equity ETFAVSCInvesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDNAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
